Viking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10 ... estimates have a direct correlation with impending stock price performance. To take advantage of this, we've ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a ...

VKTX’s shares are currently trading below the 50 and 200-day moving averages. The company is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 4. ...